NCT02112331

Brief Summary

The optimization of newborns nutrition is a challenge especially for preterm newborns for whom nutrition plays a crucial part in cerebral and global development. Human milk is considered as the best food for newborns. Several short and long-term beneficial health effects were attributed to breastfeeding and have induced the increase of human milk in preterm newborns nutrition. Whereas the chemical composition of infant formula has been optimized to mimic human milk, there is still a major difference between the structure of human milk and commercial infant formulas. It is well known in adult nutrition that the structure of emulsions influences their susceptibility to hydrolysis, such results have been obtained either on in vitro or in vivo studies. Human milk is a natural emulsion (oil in water). Lipids droplets are dispersed under the form of entities called milk fat globules (average diameter 4 µm, span 0.1-20 μm). The globules are stabilized by a trilayered membrane composed mainly of polar lipids (phospholipids, sphingolipids and gangliosides), of proteins, neutral lipids and other minor compounds. The physical treatments apply to human milk or more generally to bovine milk to pasteurize or stabilize the milk modify the structure of the natural emulsion. Heat treatment for instance induces whey proteins denaturation and the adsorption of protein aggregates on the surface of the milk fat globules. Heat treatment also leads to the denaturation of bile salt stimulated lipase. These effects limit intragastric lipolysis in preterm newborns. Conversely, reduction of milk globules size, by homogenisation of milk, increases the specific surface available for lipase adsorption and limits the lost of fat during enteral administration of milk. Such treatment could thus enhance gastric lipolysis and improve fat absorption of preterm newborns. The objective of this trial is to evaluate the effects of physical treatments (pasteurization and homogenisation by ultrasonication) applied to human milk on gastric lipolysis and milk destructuration. This trial is conducted, in vivo, on preterm newborns.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2014

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 25, 2014

Completed
7 days until next milestone

Study Start

First participant enrolled

April 1, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

April 11, 2014

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2016

Completed
Last Updated

May 23, 2023

Status Verified

May 1, 2023

Enrollment Period

1.3 years

First QC Date

March 25, 2014

Last Update Submit

May 19, 2023

Conditions

Keywords

Preterm newbornsGastric lipolysisPhysical treatmentsHuman milk

Outcome Measures

Primary Outcomes (1)

  • Percentage of triacylglycerol hydrolysis

    Monitoring of the lipolysis kinetics, using chromatography methods

    35 min

Secondary Outcomes (8)

  • Size distribution and specific surface of milk fat globule by laser light scattering

    35 min, 60 min, 90 min

  • Fat composition

    35 min, 60 min, 90 min

  • Lipolysis products

    35 min, 60 min, 90 min

  • Proteolysis products

    35 min, 60 min, 90 min

  • Kinetic of the gastric emptying

    35 min, 60 min, 90 min

  • +3 more secondary outcomes

Study Arms (2)

Raw human milk / pasteurized human milk

EXPERIMENTAL

Raw human milk compared to pasteurized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with raw milk and one with pasteurized milk. In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube : * one before the meal, * and one either 35, 60 or 90 minutes (randomized time frame) after the meal.

Other: Raw human milkOther: Pasteurized human milkOther: Gastric samples

Pasteurized human milk / pasteurized-homogenized human milk

EXPERIMENTAL

Pasteurized human milk compared to pasteurized-homogenized human milk. Two meals administration (20mL/kg) per day during 6 days in a randomized order, with an intragastric tube : one with pasteurized milk and one with pasteurized-homogenized milk. In order to characterise gastric effluents at different postprandial times after ingestion and to measure gastric lipolysis and proteolysis, at each administration two gastric samples will be collected with the intragastric tube : * one before the meal, * and one either 35, 60 or 90 minutes (randomized time frame) after the meal.

Other: Pasteurized human milkOther: Pasteurized-homogenized human milkOther: Gastric samples

Interventions

Raw human milk / pasteurized human milk
Pasteurized human milk / pasteurized-homogenized human milkRaw human milk / pasteurized human milk
Pasteurized human milk / pasteurized-homogenized human milk
Pasteurized human milk / pasteurized-homogenized human milkRaw human milk / pasteurized human milk

Eligibility Criteria

Age5 Days - 21 Days
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Premature neonates born before 32 weeks of gestation
  • Newborn dwelled near Rennes
  • Volume of enteral nutrition \> 120 mL/kg/j (Day 0)
  • Written-informed parental consent for the study

You may not qualify if:

  • Digestive congenital anomalies
  • Antecedent of enterocolitis
  • Patient included in other study
  • Abdominal distension on Day 0
  • Treatment by morphine or catecholamine on Day 0

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Rennes University Hospital

Rennes, 35000, France

Location

Related Publications (3)

  • de Oliveira SC, Bourlieu C, Menard O, Bellanger A, Henry G, Rousseau F, Dirson E, Carriere F, Dupont D, Deglaire A. Impact of pasteurization of human milk on preterm newborn in vitro digestion: Gastrointestinal disintegration, lipolysis and proteolysis. Food Chem. 2016 Nov 15;211:171-9. doi: 10.1016/j.foodchem.2016.05.028. Epub 2016 May 6.

    PMID: 27283620BACKGROUND
  • de Oliveira SC, Bellanger A, Menard O, Pladys P, Le Gouar Y, Henry G, Dirson E, Rousseau F, Carriere F, Dupont D, Bourlieu C, Deglaire A. Impact of homogenization of pasteurized human milk on gastric digestion in the preterm infant: A randomized controlled trial. Clin Nutr ESPEN. 2017 Aug;20:1-11. doi: 10.1016/j.clnesp.2017.05.001. Epub 2017 May 15.

  • de Oliveira SC, Bellanger A, Menard O, Pladys P, Le Gouar Y, Dirson E, Kroell F, Dupont D, Deglaire A, Bourlieu C. Impact of human milk pasteurization on gastric digestion in preterm infants: a randomized controlled trial. Am J Clin Nutr. 2017 Feb;105(2):379-390. doi: 10.3945/ajcn.116.142539. Epub 2017 Jan 4.

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

  • Patrick Pladys, MD, PhD

    Pôle de pédiatrie, CHU de Rennes, FRANCE

    PRINCIPAL INVESTIGATOR
  • Didier Dupont

    Agrocampus Ouest - Département AgroAlimentaire UMR 1253 INRA " Science et Technologie du Lait et de l'Oeuf ", Rennes, FRANCE

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 25, 2014

First Posted

April 11, 2014

Study Start

April 1, 2014

Primary Completion

August 1, 2015

Study Completion

April 1, 2016

Last Updated

May 23, 2023

Record last verified: 2023-05

Locations